Short-term response to alectinib and rapid progression in a lung squamous cell carcinoma patient harboring an EML4-ALK fusion: a case report
{{output}}
Background: Anaplastic lymphoma kinase (ALK) rearrangement has been identified in approximately 1% of lung squamous cell carcinomas (LUSCCs). Due to its rarity, the efficacy of anaplastic lymphoma kinase-tyrosine kinase inhibitor... ...
